Abstract
Background: TCF7L2 (Transcription Factor 7-like 2) is a transcription factor involved in the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition (EMT). While its role in various cancers is established, its clinical significance in glioma remains poorly understood. This study investigates TCF7L2 expression levels and evaluates its potential as a prognostic biomarker in glioma patients.
Method: A total of 97 glioma specimens (46 low-grade gliomas and 51 glioblastomas) were analyzed. TCF7L2 expression was quantified using quantitative real-time PCR (qRT-PCR). Statistical analyses, including chi-square tests and Kaplan-Meier survival curves, were performed to assess the relationship between TCF7L2 expression, clinicopathological characteristics, and overall survival (OS).
Results: TCF7L2 expression was significantly higher in glioblastomas compared to low-grade gliomas (p = 0.001). High expression levels were associated with advanced WHO grade, IDH wild-type status, and lack of MGMT promoter methylation. Survival analysis revealed that overexpressed TCF7L2 correlates with significantly shorter OS (p = 0.010). Multivariate analysis confirmed TCF7L2 as an independent prognostic factor (p = 0.020).
Conclusions: TCF7L2 is overexpressed in glioblastoma and serves as an independent predictor of poor prognosis, suggesting its potential as a target for future therapeutic interventions.
Introduction
Glioblastoma (GBM) is the most common and lethal primary brain tumor, characterized by intense invasiveness and resistance to standard therapies like the "Stupp protocol" (surgery, radiation, and temozolomide). Current molecular markers, such as IDH mutation and MGMT promoter methylation, provide valuable prognostic information but do not fully capture the biological heterogeneity of these tumors. TCF7L2, a key mediator of the Wnt/β-catenin pathway, has been linked to tumor cell proliferation and invasion in other malignancies. This study aims to clarify its clinical relevance and prognostic value in human glioma.
Methods
Researchers conducted a retrospective analysis of 97 patient samples (46 low-grade and 51 glioblastomas) collected at Sanbo Brain Hospital in Beijing between 2015 and 2017. mRNA levels of TCF7L2 were measured via qRT-PCR and normalized against the housekeeping gene GAPDH. Patients were categorized into "high" and "low" expression groups based on the median expression level. Survival analysis was performed using Kaplan-Meier curves to visualize overall survival (OS), and Cox proportional-hazards regression (both univariate and multivariate) was used to determine the independent prognostic value of TCF7L2.
Results
TCF7L2 Expression and Tumor Grade
The study found that TCF7L2 expression is not uniform across glioma grades. Quantitative analysis revealed that TCF7L2 mRNA levels were significantly upregulated in Grade IV glioblastomas compared to lower-grade (Grade I-II) tissues (p = 0.001). This suggests that the gene is upregulated as tumors become more undifferentiated and aggressive.
Correlation with Clinical and Molecular Features
High TCF7L2 expression was found to cluster with several indicators of poor prognosis:
- WHO Grade: Higher grades correlated with increased TCF7L2 expression (p = 0.001).
- IDH Status: High expression was significantly associated with IDH wild-type status (p = 0.001).
- MGMT Methylation: High expression correlated with a lack of MGMT promoter methylation (p = 0.001).
In neuro-oncology, this combination typically indicates a tumor that is highly resistant to standard chemotherapy.
Survival Outcomes
Kaplan-Meier survival analysis demonstrated that patients with high TCF7L2 expression had significantly shorter overall survival compared to those with low expression (p = 0.010). Furthermore, multivariate analysis identified TCF7L2 as an independent prognostic factor (Hazard Ratio = 2.56, p = 0.020), indicating its predictive value is independent of other clinical factors such as age, WHO grade, and surgical resection extent.
Discussion and Conclusion
The findings suggest that TCF7L2 plays a pivotal role in the aggressive behavior of glioblastoma, likely through its involvement in the Wnt/β-catenin pathway and EMT. Its association with IDH wild-type status and unmethylated MGMT suggests it may contribute to the treatment resistance observed in these tumors.
While the study is limited by its sample size and retrospective nature, it identifies TCF7L2 as a promising biomarker for patient stratification. Future work should focus on the underlying molecular mechanisms and investigate whether TCF7L2 itself could be a druggable target to improve outcomes for patients with this devastating disease. In conclusion, TCF7L2 is a potent independent prognostic factor that provides critical information for the clinical management of glioma.
Summary updated